This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2017 Nov 9;50(5):1701105.

doi: 10.1183/13993003.01105-2017. Print 2017 Nov.

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens

Liga Kuksa¹, Linda Barkane¹, Norbert Hittel², Rajesh Gupta³

Affiliations

Affiliations

¹ Riga East University Hospital for TB and Lung Disease Centre, Riga, Latvia.
² Otsuka Novel Products GmbH, Munich, Germany NHittel@otsuka-onpg.com.
³ Otsuka Pharmaceutical Development and Commercialization, Inc., Rockville, MD, USA.

PMID: 29122917
DOI: 10.1183/13993003.01105-2017

Free article

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens

Liga Kuksa et al. Eur Respir J. 2017.

Free article

. 2017 Nov 9;50(5):1701105.

doi: 10.1183/13993003.01105-2017. Print 2017 Nov.

Authors

Liga Kuksa¹, Linda Barkane¹, Norbert Hittel², Rajesh Gupta³

Affiliations

¹ Riga East University Hospital for TB and Lung Disease Centre, Riga, Latvia.
² Otsuka Novel Products GmbH, Munich, Germany NHittel@otsuka-onpg.com.
³ Otsuka Pharmaceutical Development and Commercialization, Inc., Rockville, MD, USA.

PMID: 29122917
DOI: 10.1183/13993003.01105-2017

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Similar articles

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD. Skripconoka V, et al. Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27. Eur Respir J. 2013. PMID: 23018916 Free PMC article.
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea.
Mok J, Kang H, Koh WJ, Jhun BW, Yim JJ, Kwak N, Lee T, Kang B, Jeon D. Mok J, et al. Eur Respir J. 2019 Nov 7;54(5):1900811. doi: 10.1183/13993003.00811-2019. Print 2019 Nov. Eur Respir J. 2019. PMID: 31285308 No abstract available.
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Polsfuss S, Hofmann-Thiel S, Merker M, Krieger D, Niemann S, Rüssmann H, Schönfeld N, Hoffmann H, Kranzer K. Polsfuss S, et al. Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074. Clin Infect Dis. 2019. PMID: 30933266
Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J. Liu Y, et al. Tuberculosis (Edinb). 2018 Jul;111:20-30. doi: 10.1016/j.tube.2018.04.008. Epub 2018 May 3. Tuberculosis (Edinb). 2018. PMID: 30029909 Review.
Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
Sotgiu G, Pontali E, Centis R, D'Ambrosio L, Migliori GB. Sotgiu G, et al. Expert Rev Anti Infect Ther. 2015 Mar;13(3):305-15. doi: 10.1586/14787210.2015.1011127. Epub 2015 Feb 3. Expert Rev Anti Infect Ther. 2015. PMID: 25645397 Review.

See all similar articles

Cited by

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.
Pecora F, Dal Canto G, Veronese P, Esposito S. Pecora F, et al. Microorganisms. 2021 May 17;9(5):1074. doi: 10.3390/microorganisms9051074. Microorganisms. 2021. PMID: 34067732 Free PMC article. Review.
Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.
Lardizabal AA, Khan AN, Bamrah Morris S, Goswami ND. Lardizabal AA, et al. MMWR Morb Mortal Wkly Rep. 2018 Sep 7;67(35):996-997. doi: 10.15585/mmwr.mm6735a6. MMWR Morb Mortal Wkly Rep. 2018. PMID: 30188880 Free PMC article. No abstract available.
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, De Azevedo V, Kock Y, Steele SJ, Shroufi A, Ade S, Alikhanova N, Benedetti G, Edwards J, Cox H, Furin J, Isaakidis P. Mohr E, et al. Eur Respir J. 2018 Jun 14;51(6):1800017. doi: 10.1183/13993003.00017-2018. Print 2018 Jun. Eur Respir J. 2018. PMID: 29724920 Free PMC article.
Recent evidence on delamanid use for rifampicin-resistant tuberculosis.
Pontali E, Centis R, D'Ambrosio L, Toscanini F, Migliori GB. Pontali E, et al. J Thorac Dis. 2019 Mar;11(Suppl 3):S457-S460. doi: 10.21037/jtd.2018.11.26. J Thorac Dis. 2019. PMID: 30997247 Free PMC article. No abstract available.
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.
Dookie N, Ngema SL, Perumal R, Naicker N, Padayatchi N, Naidoo K. Dookie N, et al. Clin Microbiol Rev. 2022 Dec 21;35(4):e0018019. doi: 10.1128/cmr.00180-19. Epub 2022 Oct 6. Clin Microbiol Rev. 2022. PMID: 36200885 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Other Literature Sources
- scite Smart Citations